#161786

TOV-3392D cell line

Cat. #161786

TOV-3392D cell line

Cat. #: 161786

Organism: Human

Tissue: Derived from solid tumor of patient diagnosed with epithelial ovarian cancer with a clear cell carcinoma subtype

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Anne-Marie Mes-Masson and Diane Provencher

Institute: Centre Hospitalier de L’université de Montréal

Primary Citation: Sauriol A et al. 2020. Cancers. 12(8):2222. PMID: 32784519

Tool Details
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: TOV-3392D cell line
  • Alternate name: TOV-3392D
  • Organism: Human
  • Gender: Female
  • Tissue: Derived from solid tumor of patient diagnosed with epithelial ovarian cancer with a clear cell carcinoma subtype
  • Donor: Grade 3 – Stage IIIC; Mutations: K-RAS2; Pre-treatment for ovarian cancer/post-treatment for breast cancer 3 years before
  • Morphology: Characteristic flat epithelial morphology, grew in dense clusters, and gained little confluence
  • Growth properties: Adherent
  • Crispr: No
  • Receptors of note: No
  • Description: Epithelial ovarian cancer cell lines spontaneously derived from solid tumors of patient diagnosed with clear-cell carcinoma suubtype. Sample was taken from the right ovary. Cell line produces tumors in mice upon SC injection
  • Production details: Established using the Scrape method where tumor tissue was scraped into a 100mm plate with complete OSE medium and maintained for 40 days with medium replaced weekly.
  • Additional notes: Patient 3392 had previous personal history of breast cancer and was naive to ovarian cancer treatment but received prior chemotherapy for breast cancer. Patient was age 42 at diagnosis and har prior history of breast cancer. Treatment included 5-fluorouracil, epirubicin, cyclo-phosphamide, radiotherapy, and trastuzumab. Sampling was done during 2007.

Handling

  • Growth medium: OSE medium contains 10% FBS, 0.5ug/mL amphotericin B and 50 ug/mL gentamicin
  • Temperature: 37° C
  • Atmosphere: Low oxygen conditions of 7% O2 and 5% CO2
  • Cultured in antibiotics: Amphotericin B and Gentamicin

References

  • Gaia-Oltean et al. 2021. Exp Ther Med. 21(3):243. PMID: 33603851 Canals Hernaez et al. 2020. J Immunother Cancer. 8(2):e001128. PMID: 33243933 Borzdzi?owska et al. 2022. Biomedicines. 11
  • 10(5):1116. PMID: 35625852 Meng et al. 2023. J Anim Sci. 3
  • 101:skad215. PMID: 37351870 Koni et al. 2020. Int J Mol Sci. 18
  • 21(20):7697. PMID: 33080952